Conference Coverage

Most data reassure regarding TNF inhibitors and cancer


 

EXPERT ANALYSIS FROM PERSPECTIVES IN RHEUMATIC DISEASES 2013

Dr. McInnes disclosed that he has been a speaker, adviser, and/or investigator for Janssen, Roche, Pfizer, BMS, and Novartis. The meeting was held by Global Academy for Medical Education. GAME and this news organization are owned by Frontline Medical Communications.

Pages

Recommended Reading

FDA Advises Caution When IV Methotrexate-PPI Used Together
MDedge Hematology and Oncology
Extramammary Paget's Needs More Than Mohs
MDedge Hematology and Oncology
Slowed Infusions Cut Hypersensitivity Reactions in Rituximab Desensitization
MDedge Hematology and Oncology
Panel Recommends Tofacitinib Approval for Refractory RA
MDedge Hematology and Oncology
Biologics for RA Do Not Increase Solid Cancer Risk
MDedge Hematology and Oncology
FDA Approves REMS for Long-Acting Opioids
MDedge Hematology and Oncology
Biologic Agents for RA Don't Appear to Raise Malignancy Risk
MDedge Hematology and Oncology
Anti-TNFs Have Not Raised Lymphoma Risk
MDedge Hematology and Oncology
Bill seeks to keep biologic copays down
MDedge Hematology and Oncology
All glucocorticoids linked to increased risk of VTE
MDedge Hematology and Oncology